Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.Methods Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and <24 ('severe dysfunction', n = 212). Risks of major cardiovascular events, death and hypoglycaemia and interactions with treatment were assessed using Cox proportional hazards analysis.Results Relative to normal function, both mild and severe cognitive dysfunction significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p < 0.05), cardiovascular death (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p <or= 0.05) and all-cause death (1.33, 95% CI 1.16-1.54 and 1.50, 95% CI 1.06-2.12; both p < 0.03). Severe, but not mild, cognitive dysfunction increased the risk of severe hypoglycaemia (HR 2.10, 95% CI 1.14-3.87; p = 0.018). There was no evidence of heterogeneity of treatment effects on cardiovascular outcomes in subgroups defined by cognitive function at baseline.Conclusions/interpretation Cognitive dysfunction is an independent predictor of clinical outcomes in patients with type 2 diabetes, but does not modify the effects of BP lowering or glucose control on the risks of major cardiovascular events.Trial registration ClinicalTrials.gov NCT00145925.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The person with cognitive disorders is at high risk of future severe hypoglycemic episodes, possibly because of medication errors (19,56,57)”
From Hypoglycemia (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Risk factors for hypoglycemia in people with type 2 diabetes include advancing age (18), severe cognitive impairment (19), poor health literacy (20), food insecurity (21), increased A1C (18,22), hypoglycemia unawareness (23), duration of insulin therapy, renal impairment and neuropathy (22).”
From Hypoglycemia (2018) · cites this paper as [19]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Treatment with statin therapy has been documented to protect against stroke, both in primary460 and secondary studies, based on data from meta-analysis36 and a single trial, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL).461”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [461]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“First, the MMSE was originally designed as a screening test for dementia and not especially for the assessment of milder degrees of cognitive dysfunction [33].”
MethodWild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · cited 1×
“Diabetes and cognitive dysfunction represent serious health problems in the ageing population, with the prevalence of both conditions projected to increase in most parts of the world [1, 2].”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 4×
“The main results have been reported previously [17, 18].”
BackgroundResultInfluentialGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332 · cited 1×
“Diabetes and cognitive dysfunction represent serious health problems in the ageing population, with the prevalence of both conditions projected to increase in most parts of the world [1, 2].”
BackgroundSarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · cited 4×
“2,777 (32.0) 572 (25.6) 44 (20.8) <0.001 HbA1c, % (SD) 7.5 (1.5) 7.6 (1.7) 7.7 (1.8) <0.001 Systolic BP, mmHg (SD) 144 (21.2) 147 (22.8) 147 (22.5) <0.001 Diastolic BP, mmHg (SD) 81 (10.8) 80 (11.3) 80 (10.7) 0.102 Serum total cholesterol, mmol/l (SD) 5.2 (1.2) 5.3 (1.2) 5.2 (1.1) 0.004 Serum creatinine, µmol/l 86.3 (…”
MethodInfluentialPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929 · cited 1×
“Cognition was defined as ‘normal’ for MMSE scores of ≥28, as ‘mild dysfunction’ for scores of 24–27, and as ‘severe dysfunction’ for scores <24 [20].”
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054 · cited 3×
“The main results have been reported previously [17, 18].”
BackgroundResultSelf-citationCognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Cukierman, T., Gerstein, H. C., & Williamson, J. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0023-4 · Cited by 1,049 · cited 1×
“6-fold greater risk of dementia compared with people without diabetes [7].”
BackgroundCognitive Dysfunction and Diabetes Mellitus
Kodl, C. T., & Seaquist, E. R. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0034 · Cited by 802
Insulin Sensitivity and Atherosclerosis
Howard, G., O’Leary, D. H., Zaccaro, D., Haffner, S., Rewers, M., Hamman, R., Selby, J. V., Saad, M. F., Savage, P., & Bergman, R. (1996) · Circulation · doi:10.1161/01.cir.93.10.1809 · Cited by 729
Cited by
Items 101–200 of 248
Dias, I. H. K., & Griffiths, H. R. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213508747 · Cited by 20
“In the glucose control intervention study, cognitive function was an independent predictor of glycaemic control, but the risk of cognitive decline or dementia was not decreased by improving glycaemic control.(8) AGEs, carbonylation of LDL, which is indicative of oxidative stress, and glycation are shared common risk f…”
BackgroundExpert Consensus on Cognitive Dysfunction in Diabetes
Yang, Y., Zhao, J., & Yu, X. (2022) · Current Medical Science · doi:10.1007/s11596-022-2549-9 · Cited by 18
Shigemoto, S., Imbe, H., Fujisawa, R., Sasagawa, A., Watanabe, D., Tachibana, M., Sano, H., Kanatsuna, N., Terasaki, J., & Imagawa, A. (2022) · Diabetology International · doi:10.1007/s13340-022-00588-9 · Cited by 18
“Not only is hypoglycemia a risk of developing dementia in type 2 diabetes, but it has been reported that diabetic patients who develop dementia are at an even higher risk of developing hypoglycemic attacks [19].”
BackgroundChai, S., Liu, F., Yu, S., Yang, Z., & Sun, F. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14015 · Cited by 19
Umegaki, H. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0375-0 · Cited by 19
Yuan, X., Zhang, L., Sui, R., & Wang, Z. (2021) · Neurological Research · doi:10.1080/01616412.2021.1908659 · Cited by 19
Management of Hyperglycemia in Older Adults with Type 2 Diabetes
Gandhi, G. Y., & Mooradian, A. D. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00910-1 · Cited by 18
“Cognitive impairment in patients with diabetes is associated with poorer diabetes self-management and glycemic control [22], an increased frequency of hospital admissions and occurrence of severe hypoglycemic episodes [23, 24], and an increased occurrence of major cardiovascular events and death [25].”
BackgroundType 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 18
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Katsiki, N., Kotsa, K., Stoian, A. P., & Mikhailidis, D. P. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200909142658 · Cited by 17
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 17
Lee, J., Kim, T. M., Kim, H., Lee, S.-H., Cho, J. H., Lee, H., Yim, H. W., Yoon, K., & Kim, H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0064 · Cited by 15
New Horizons—Cognitive Dysfunction Associated With Type 2 Diabetes
Moran, C., Than, S., Callisaya, M. L., Beare, R. J., & Srikanth, V. K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab797 · Cited by 17
Wal, P., Tyagi, S., Pal, R. S., Yadav, A., & Jaiswal, R. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220426091238 · Cited by 16
Relationship between cognitive function in individuals with diabetic foot ulcer and mortality
Sela, Y., Grinberg, K., Cukierman‐Yaffe, T., & Natovich, R. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00901-1 · Cited by 14
Avoiding hypoglycaemia: a new target of care for elderly diabetic patients
Wong, C. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144494 · Cited by 17
Neuroactive Steroid–Gut Microbiota Interaction in T2DM Diabetic Encephalopathy
Diviccaro, S., Cioffi, L., Piazza, R., Caruso, D., Melcangi, R. C., & Giatti, S. (2023) · Biomolecules · doi:10.3390/biom13091325 · Cited by 14
“Moreover, cognitive impairment predisposes DM patients to treatment-related complications, such as severe hypo- or hyper-glycemic episodes [9,10].”
BackgroundWestall, S., Narayanan, R. P., Watmough, S., Irving, G. J., Furlong, N. J., McNulty, S., Bujawansa, S., & Hardy, K. J. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0764 · Cited by 13
Lega, I. C., Yale, J.-F., Chadha, A., Paty, B., Roscoe, R., Snider, M., Steier, J., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.08.003 · Cited by 12
“…marker for undiagnosed cognitive impairment, as individuals with cognitive disorders are at high risk of future hypoglycemic episodes, including level 3 hypoglycemia, possibly because of medication errors and irregular eating patterns [30,49,50] (see “ Diabetes in Older People ” chapter, p. S283).”
BackgroundLi, Z., Wang, S., Liu, S., Gong, X., Wang, Y., Wu, D., Yang, M., Li, R., Li, H., Li, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.997260 · Cited by 12
“An Australia cohort study of 11,140 patients with diabetes focused on adults (≥55 years) demonstrated that CI was associated with an increased risk of all-cause and cardiovascular mortality (30).”
BackgroundCukierman‐Yaffe, T., Gerstein, H. C., Miller, M. E., Launer, L. J., Williamson, J. D., Horowitz, K. R., Ismail‐Beigi, F., & Lazar, R. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3480 · Cited by 13
Peng, J., Yang, S., Zhou, C., Qin, C., Fang, K., Tan, Y. C., Da, J., Zhang, J., & Zha, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-72327-w · Cited by 11
Ma, H., He, S., Li, Y., Zhang, X., Chang, H., Du, M., Yan, C., Jiang, S., Gao, H., Zhao, J., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04064-0 · Cited by 11
Niikawa, T., Ozeki, T., Kato, M., & Ikoma, Y. (2008) · Horticultural Research (Japan) · doi:10.2503/hrj.7.123 · Cited by 11
(2018) · Europe PMC (PubMed Central) · Cited by 10
Xu, F., Hu, J., Li, X., Yang, L., Jiang, S., Jiang, T., Cheng, B., Du, H., Wang, R., Deng, Y., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111211 · Cited by 10
Qin, P., He, J., Yang, X., Chen, S., Chen, X., Jiang, H., Fung, A. W. T., Wang, Z. J., & Lau, J. T. F. (2022) · JMIR Public Health and Surveillance · doi:10.2196/32968 · Cited by 11
Sugimoto, T., Araki, A., Fujita, H., Honda, K., Inagaki, N., Ishida, T., Kato, J., Kishi, M., Kobayashi, K., Kouyama, K., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.680341 · Cited by 11
“Several randomized controlled trials were conducted in this population with a focus on the effects of intensive glycemic control on cognitive function (de Galan et al., 2009; Launer et al., 2011; Koekkoek et al., 2012).”
BackgroundCognitive impairment in type 2 diabetes mellitus: prospects for the use of metformin
Pashkovska, N. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1274 · Cited by 10
Hypoglykämien und zentrales Nervensystem
Erbguth, F. J. (2013) · Der Diabetologe · doi:10.1007/s11428-012-0911-4 · Cited by 9
A Compressive Review on Novel Molecular Target of Diabetic Nephropathy
Jaiswal, A., Semwal, B. C., & Singh, S. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00233 · Cited by 10
Gungabissoon, U., Broadbent, M. T. M., Perera, G., Ashworth, M. J., Galwey, N. W., & Stewart, R. J. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.04.045 · Cited by 10
Talfournier, J., Bitu, J., Paquet, C., Gobron, C., Guillausseau, P.-J., Hugon, J., & Dumurgier, J. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.008 · Cited by 11
Diabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neumann, S. A. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_10 · Cited by 13
Hu, J., Li, Q., Jiang, S., Deng, Y., Yang, L., Du, M., He, S., Xu, F., Yan, C., Gao, W., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111245 · Cited by 9
Zhong, P., Tan, S., Zhu, Z., Zhang, J., Chen, S., Huang, W., He, M., & Wang, W. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.04.010 · Cited by 8
Mansouri, S., Lietzau, G., Lundberg, M., Nathanson, D., Nyström, T., & Patrone, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156867 · Cited by 8
Hypoglycaemia in Type 2 Diabetes and in Elderly People
Zammitt, N. N., & Frier, B. M. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch12 · Cited by 9
Piro, S., & Purrello, F. (2021) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n457 · Cited by 8
Wei, J., Xu, H., Zhang, D. “., Tang, H., Wang, T., Steck, S. E., Divers, J., Zhang, J., & Merchant, A. T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230398 · Cited by 7
Glycemia and cardiovascular risk: challenging evidence based medicine.
Kitsios, K., Τσάπας, Α., & Karagianni, P. (2011) · PubMed Central · Cited by 10
Zhang, Z., Ma, L., Huang, L., Zhu, Y., Guo, H., Wang, L., Zhang, W., & Tan, L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1457160 · Cited by 6
Strain, W. D., Paldánius, P. M., & Novartis Pharma AG, B. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.62 · Cited by 8
“ADVANCE (NCT00949286)(20) and VADT (NCT00032487)(21) did not show a corresponding increase in cardiac death, nor did they demonstrate any substantial reductions in diabetes-related events.(20) Nevertheless, a paradigm shift had arrived; from targeting aggressive glucose lowering to avoiding adverse events, such as hyp…”
BackgroundSchwartz, S. S., & Herman, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394805 · Cited by 6
Feil, D. G., & POGACH, L. M. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101525 · Cited by 6
Harris, K., Gong, J., MacMahon, S. W., Xu, Y. H., Shajahan, S., Harrap, S. B., Poulter, N. R., Marre, M., Hamet, P., Mancia, G., et al. (2024) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2024.100372 · Cited by 6
Self-citationWan, S., Yan, H., Sun, Q., Zhu, J., Wang, H., Qu, K., & Yi, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70201 · Cited by 7
RetractedOptimal Glycemic Control in the Elderly: Where is the Evidence and Who Should Be Targeted?
Tessier, D. (2011) · Aging Health · doi:10.2217/ahe.10.86 · Cited by 5
“Furthermore, the ADVANCE trial stratified participants according to their mini-mental state examination (MMSE) score of 28–30, 24–27 and equal to or below 23 [38].”
MethodClayton, D., Woo, V. C., & Yale, J. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.088 · Cited by 6
RetractedMohan, V., WANGNOO, S. K., Das, S., Dhediya, R., & Gaurav, K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1168 · Cited by 7
Influence of cognitive impairment on the management of ischaemic stroke
Murao, K., Bombois, S., Cordonnier, C., Hénon, H., Bordet, R., Pasquier, F., & Leys, D. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.01.665 · Cited by 6
Когнітивні порушення при цукровому діабеті типу 2: роль гіпоглікемізуючої терапії
Pashkovska, N. V. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.1.2018.127097 · Cited by 10
Association of Hypoglycemia With Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus
Mehta, H. B., Mehta, V., & Goodwin, J. S. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz053 · Cited by 6
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
Cukierman‐Yaffe, T., Gerstein, H. C., Basile, J., Bethel, M. A., Cardona-Muñóz, E. G., Conget, I., Dagenais, G. R., Franek, E., Hall, S., Hâncu, N., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac200 · Cited by 5
Muthuppalaniappan, V. M., Sheaff, M. T., & Yaqoob, M. M. (2015) · Medicine · doi:10.1016/j.mpmed.2015.06.007 · Cited by 11
Alsharif, A. A., Wong, I. C. K., Ma, T., Lau, W. C. Y., Alhamed, M., Alwafi, H. H., & Wei, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1177636 · Cited by 4
Practical considerations for managing patients with diabetes and dementia
Mair, M. L., Athavale, R., & Abdelhafiz, A. H. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1395692 · Cited by 4
Observational analyses from ADVANCE and ADVANCE‐ON
Chalmers, J. P., & Woodward, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13894 · Cited by 4
Self-citationMEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - A CROSS-SECTIONAL STUDY
T, P. R., Prashanthi, B., FATHIMA, A. A., FIRDOSE, A., Naser, S. M., BEGUM, N., & Begum, K. (2019) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2019.v12i10.34787 · Cited by 7
“Studies have reported that strict metabolic control can delay or prevent the progression of complications associated with diabetes [20].”
BackgroundVascular Dementia and Cognitive Impairment
Seshadri, S. S., Economos, A., & Wright, C. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00017-7 · Cited by 4
Shajahan, S., Woodward, M., Anderson, C. S., Carcel, C., Wang, N., Tully, P. J., Peters, R., Harrap, S. B., Poulter, N. R., Mancia, G., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044061 · Cited by 3
Self-citationChao, H.-Y., Lin, M.-C., Fang, T., Hsu, M.-C., Liang, C., & Lee, M. (2025) · Biomedicines · doi:10.3390/biomedicines13020340 · Cited by 4
Vascular Dementia and Cognitive Impairment
Seshadri, S. S., Caunca, M. R., & Rundek, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-69424-7.00018-1 · Cited by 3
Fanelli, C. G., Lucidi, P., Bolli, G. B., & Porcellati, F. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_22 · Cited by 3
Noroozıan, M., Shakiba, A., & Mohammadian, F. (2024) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2022.1551.2 · Cited by 4
Niu, X., Chang, J. J., Corrada, M. M., Bullock, A. K., Winchester, B., Manson, S. M., O’Connell, J., & Jiang, L. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21040496 · Cited by 3
Взаимосвязь гипогликемии и когнитивных нарушений у пожилых пациентов с сахарным диабетом 2 типа
Bulgakova, S. V., Merzlova, P. Y., Kurmaev, D. P., & Treneva, E. V. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-2-2024-108-116 · Cited by 3
Diabetes and Depression: Management in Ordinary Clinical Conditions
Hellman, R., & Ciechanowski, P. S. (2010) · Wiley eBooks · doi:10.1002/9780470667309.ch5 · Cited by 3
Les hypoglycémies chez les diabétiques âgés : conséquences sur les fonctions cognitives
Bauduceau, B., Doucet, J., & Bordier, L. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70270-x · Cited by 4
Buysschaert, M., Bordier, L., Bauduceau, B., Buysschaert, M., Floch, J. L., Verny, C., & Doucet, J. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30010-9 · Cited by 5
Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?
Feldman, R. D., Harris, S. B., Hegele, R. A., Pickering, J. G., & Rockwood, K. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.002 · Cited by 3
Assessment of Cognitive Function in Type 2 Diabetes
Cuevas, H. E. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2017.04.026 · Cited by 3
Rostamian, S., van Buchem, M. A., Jukema, J. W., Gussekloo, J., Poortvliet, R. K. E., de Cren, A. J. M., & Sabayan, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00307 · Cited by 4
“Most of the studies that investigated the association of cognitive impairment with future risk of cardiovascular events were performed in middle-aged and young old people (de Galan et al., 2009; Wiberg et al., 2010; O’Donnell et al., 2012).”
BackgroundManagement of type 2 diabetes mellitus and prediction of cardiovascular complications
van Dieren, S., Health, C., Health, J. O. C., Economics, E. &. H., van der Schouw, Y. T., Beulens, J. W. J., & Peelen, L. M. (2013) · Utrecht University Repository (Utrecht University) · Cited by 5
Pedersen, F. N., Lois, N., Biessels, G. J., Exalto, L. G., Pérez‐Hoyos, S., Simó, R., & Grauslund, J. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.02.004 · Cited by 2
Noninsulin Diabetes Therapies in Older Adults
Tekin, Z., & Zimmerman, R. S. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.03.001 · Cited by 3
Bulgakova, S. V., Merzlova, P. Y., Kurmaev, D. P., & Treneva, E. V. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-1-2024-30-39 · Cited by 3
Diabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neuman, S. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_10-1 · Cited by 2
Ожирение и болезнь Альцгеймера
Pashkovska, N. V., Pankiv, V. І., & Pashkovska, O. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.1.2020.199121 · Cited by 3
Ghanem, A., Ubben, T., Wienemann, H., & Spangenberg, T. (2020) · Springer eBooks · doi:10.1007/978-3-030-49586-2_11 · Cited by 2
Fanelli, C. G., Lucidi, P., Bolli, G. B., & Porcellati, F. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_22-2 · Cited by 2
Park, J., & Yoon, K. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_10 · Cited by 3
Hypoglycemie bij diabetes: relevant voor het cardiovasculaire risico en de cognitie?
Kooy, A. (2011) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-011-0016-5 · Cited by 2
Patel, A. V., & Libman, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_37 · Cited by 1
Self-citationLiu, H., He, X., Tang, L., Deng, Y., & Yan, L. J. (2023) · Medicine · doi:10.1097/md.0000000000034440 · Cited by 1
Nordheim, D. V., Herrick, C., Verdecias, N., Garg, R., Kreuter, M. W., & McQueen, A. (2024) · Diabetes Spectrum · doi:10.2337/ds23-0067 · Cited by 1
Patel, R. D., & Patel, H. V. (2024) · Indian Journal of Pharmacy Practice · doi:10.5530/ijopp.17.3.40 · Cited by 1
Yu, Y., Hu, B., Yu, X., Cui, Y., Cao, X., Ni, M.-H., Li, S., Dai, P., Sun, Q., Bai, X., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111313 · Cited by 1
Makasi, J. S., Goruntla, N., Bommireddy, B. R., Mopuri, B., Easwaran, V., Mantargi, M. J. S., Bandaru, V., Ezeonwumelu, J. O. C., & Yadesa, T. M. (2025) · Health Science Reports · doi:10.1002/hsr2.71548 · Cited by 1
“This can predispose diabetic patients to experience treatment ‐ related complications, such as acute severe hyper ‐ or hypoglycaemic events, and increased risk of micro ‐ and macrovascular complications of diabetes [30, 31].”
Diabetes and cognitive impairment—insights for early diagnosis and management
Mishra, R., Kumar, V. U., Murti, K., Gupta, A. K., Kumar, N., & Quadri, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00026-8 · Cited by 1
Zhou, L., Yang, Z., Ren, L., Hu, G., Wang, J., Li, S., Peng, X., Zhao, M., Li, Q., Zhao, Z., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-102070 · Cited by 1
Pei, F., & Sun, J. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0175-2 · Cited by 1
“cose (hyperglycemia) with consequent evolution toward DM2, dyslipidemia, hypertension, and abdominal type of obesity [11].”
RetractedShaw, K. M. (2010) · Practical Diabetes · doi:10.1002/pdi.1487 · Cited by 1
Vascular Dementia and Vascular Cognitive Decline
Seshadri, S. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5478-8.10017-x · Cited by 1
Les troubles cognitifs chez les patients diabétiques âgés. Apport de l’étude Gérodiab
Bauduceau, B., Bordier, L., Floch, J. P. L., Verny, C., & Doucet, J. (2016) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30679-x · Cited by 2
Use, Safety, and Effectiveness of Diabetes Medications in Older Nursing Home Residents
Zullo, A. R. (2016) · doi:10.7301/z05d8q9h · Cited by 1
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_24 · Cited by 1
Fanelli, C. G., Lucidi, P., Bolli, G. B., & Porcellati, F. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_22 · Cited by 5
Kognitivne motnje pri bolnikih s sladkorno boleznijo tipa 2
Špeh, A., Šatej, N., Janež, A., & Kramberger, M. G. (2022) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3302 · Cited by 1
Zhou, J., Shi, W., Jiang, Y., Li, Y., & Yue, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01938-8 · Cited by 1
“In addition, cognitive dysfunction significantly increases the risks of cardiovascular events and all-cause mortality, imposing a heavy burden on families and society [8].”
Diabetes, Depression, and Cognitive Disorders
Holt, R. I. G. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_24-1 · Cited by 1
Metadata
- Authors
- for the ADVANCE Collaborative group, de Galan, B. E., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M., Grobbee, D. E., Hackett, M., Hamet, P., Heller, S. R., Lisheng, L., MacMahon, S., Mancia, G., Neal, B., Pan, C. Y., Patel, A., Poulter, N., Travert, F., & Woodward, M.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- National Health Service (GB)
- St Mary's Hospital (GB)
- Université Pierre-et-Marie-Curie (FR)
- Corresponding author
- Zoungas, S.
- ORCID
- Venue
- Diabetologia
- Published
- 2009-08-18
- Volume
- 52
- Issue
- 11
- Pages
- 2328-2336
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1980054867
- Cited by
- 243
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 16 · 2021: 14 · 2020: 16 · 2019: 17 · 2018: 22 · 2017: 9 · 2016: 14 · 2015: 16 · 2014: 13 · 2013: 18 · 2012: 15
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Servier
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, cognitive impairment, cardiovascular disease, cardiovascular mortality, all-cause mortality, hypoglycemia, metformin, glimepiride, blood pressure reduction, glycemic control, treatment effect heterogeneity, Mini-Mental State Examination, ADVANCE trial, cardiovascular risk stratification, cognitive screening, stroke risk, myocardial infarction risk
- MeSH terms
- Aged, Antihypertensive Agents, Cognition, Cognition Disorders, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Combinations, Drug Therapy, Combination, Educational Status, Female, Gliclazide, Humans, Hypoglycemia, Hypoglycemic Agents, Indapamide, Male, Mental Status Schedule, Myocardial Infarction, Risk Factors, Stroke, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.